NKF KDOQI GUIDELINES

KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease

Tables
Figures
Algorithms
Acronyms and Abbreviations
Work Group Membership
Foreword
Introduction
Guideline Statements
Background
Methods for Analysis of Literature

Clinical Practice Guidelines

• Guideline 1.   Evaluation of Calcium and Phosphorus Metabolism
• Guideline 2.   Assessment of Bone Disease Associated With CKD
• Guideline 3.   Evaluation of Serum Phosphorus Levels
• Guideline 4.   Restriction of Dietary Phosphorus in Patients With CKD
• Guideline 5.   Use of Phosphate Binders in CKD
• Guideline 6.   Serum Calcium and Calcium-Phosphorus Product
• Guideline 7.   Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients
• Guideline 8.   Vitamin D Therapy in CKD Patients
  • Guideline 8A.   Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD
  • Guideline 8B.   Vitamin D Therapy in Patients on Dialysis (CKD Stage 5)
• Guideline 9.   Dialysate Calcium Concentrations
• Guideline 10.   ß₂-Microglobulin Amyloidosis
• Guideline 11.   Aluminum Overload and Toxicity in CKD
• Guideline 12.   Treatment of Aluminum Toxicity
• Guideline 13.   Treatment of Bone Disease in CKD
  • Guideline 13A.   Hyperparathyroid (High-Turnover) and Mixed (High-Turnover With Mineralization Defect) Bone Disease
  • Guideline 13B.   Osteomalacia
  • Guideline 13C.   Adynamic Bone Disease
• Guideline 14.   Parathyroidectomy in Patients With CKD
• Guideline 15.   Metabolic Acidosis
• Guideline 16.   Bone Disease in the Kidney Transplant Recipient

The Overall Approach to the Management of Bone Metabolism and Disease in CKD Patients

Biographical Sketches of Work Group Members

References

Complete Bibliography From Evidence Reports

Disclaimer

© 2003 National Kidney Foundation, Inc.